ArticleInternational urology and nephrology2022
Bladder cancer biomarker screening based on non-targeted urine metabolomics.
Article in International urology and nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Review
- LC-MS-Based Metabolomics and Proteomics Sample Preparation of Urine: Methods and Multi-Omics Integration.Advances in experimental medicine and biology · 2026Review
- Broadband Collision-Induced Dissociation Mass Spectrometry Imaging.Journal of the American Society for Mass Spectrometry · 2025Article
- Integrative analysis of serum microorganisms and serum metabolomics in osteoporosis patients based on 16S rDNA sequencing and UHPLC/MS-based metabolomics.Frontiers in medicine · 2025Article
- Magnetic 3D macroporous MOF oriented urinary exosome metabolomics for early diagnosis of bladder cancer.Journal of nanobiotechnology · 2024Article
- Metabolomics for the diagnosis of bladder cancer: A systematic review.Asian journal of urology · 2024Review
- Metabolomic profiling of human bladder tissue extracts.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Evaluating changes in firefighter urinary metabolomes after structural fires: an untargeted, high resolution approach.Scientific reports · 2023Article
- Targeted quantitative metabolomics with a linear mixed-effect model for analysis of urinary nucleosides and deoxynucleosides from bladder cancer patients before and after tumor resection.Analytical and bioanalytical chemistry · 2023Article
- Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.Scientific reports · 2023Article
- Metabolomic and elemental profiling of blood serum in bladder cancer.Journal of pharmaceutical analysis · 2022Article
- A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeBladder cancer is one of the most common malignancies of the urinary system, and its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury and infection. This study aims to use non-targeted metabolomics methods to screen for metabolites that are significantly different between the urine of bladder cancer patients and cancer-free controls.
methodsIn this study, liquid chromatography-mass spectrometry was used to analyze the urine of bladder cancer patients (n = 57) and the cancer-free controls (n = 38) by non-targeted metabolomic analysis and metabolite identification.
resultsThe results showed that there were significant differences in the expression of 27 metabolites between bladder cancer patients and the cancer-free controls.
conclusionIn the multivariate statistical analysis of this study, the urinary metabolic profile data of bladder cancer patients were analyzed, and the receiver operating characteristic curve analysis showed that it is possible to perform non-invasive clinical diagnoses of bladder cancer through these candidate biomarkers.
Indexed as
Identifiers
34850327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.